BO-112 With Pembrolizumab in Unresectable Malignant Melanoma

NCT04570332 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: BO-112 plus pembrolizumab
PROCEDURE: Tissue Biopsies

Sponsor

Highlight Therapeutics

Collaborators

[object Object]